Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2025; 31(6): 100517
Published online Feb 14, 2025. doi: 10.3748/wjg.v31.i6.100517
Innovative approaches in predicting outcomes for rectal neuroendocrine tumors
Mahmoud Nassar, Bahaaeldin Baraka, Andrew H Talal
Mahmoud Nassar, Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY 14221, United States
Mahmoud Nassar, Department of Research, American Society for Inclusion, Diversity, and Equity in Healthcare, Lewes, DE 19958, United States
Bahaaeldin Baraka, Medical Oncologist, Oncology, Nottingham University Hospitals, City Hospital, Nottingham NG5 1PB, United Kingdom
Andrew H Talal, Department of Medicine, University at Buffalo, State University of New York, Buffalo, NY 14203, United States
Author contributions: Nassar M, Baraka B, and Talal AH contributed equally to the writing and editing of the manuscript; Talal AH additionally reviewed the article for critical content.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. Talal AH reports grant and research support from Gilead, Abbott Laboratories, Novo Nordisk, AstraZeneca, and Salix. Additionally, Talal AH serves on committees or as an advisor for Gilead, AbbVie, and Novo Nordisk.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mahmoud Nassar, MD, MSc, PhD, Academic Editor, Staff Physician, Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Received: August 18, 2024
Revised: November 5, 2024
Accepted: December 9, 2024
Published online: February 14, 2025
Processing time: 144 Days and 15.1 Hours
Core Tip

Core Tip: The GATIS score is a new prognostic tool for rectal neuroendocrine neoplasms, enhancing accuracy by combining clinical and pathological factors. Its use in clinical decision-making could transform treatment approaches by tailoring them to patient risk levels, guiding management, and informing surveillance to detect early recurrence. This tool also aids in selecting clinical trial candidates, which could promote research and the development of new therapies.